Efficacy of Renin Angiotensin Aldosterone System Inhibitors on Cardiovascular Outcomes in Hypertensive Population: A Network Meta-analysis of Randomized Controlled Trials - PubMed
3 hours ago
- #cardiovascular outcomes
- #hypertension
- #RAAS inhibitors
- RAAS inhibitors are widely used for lowering blood pressure, but the optimal choice for reducing cardiovascular events is unclear.
- A network meta-analysis of 43 randomized controlled trials compared the efficacy of different RAAS inhibitors on cardiovascular outcomes in hypertensive patients.
- Mineralocorticoid receptor antagonists (MRAs) significantly reduced the risk of major adverse cardiovascular events (MACE) compared to placebo, ARBs, and DRIs.
- MRAs showed a non-significant trend toward benefit compared to ACE inhibitors.
- MRAs were particularly effective in reducing cardiovascular mortality and heart failure, while ACEIs were more effective against myocardial infarction and ARBs against stroke.
- The protective effect of MRAs was most pronounced in patients with heart failure and consistent across subgroups with diabetes or chronic kidney disease.
- The study suggests MRAs may merit earlier consideration in hypertension management, pending confirmatory trials.